Patient-Derived Xenograft Models of Colorectal Cancer

Benefits of Crown Bioscience's Colon cancer Patient derived xenograft model research

Our Colorectal cancer Patient-derived xenograft models offer the most translational preclinical model for efficacy screening in Colon cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, Patient derived xenograft reflects the heterogeneity and diversity of the human patient population. Colon cancer PDX model will give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime^® Rectal cancer PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.